Q1 EPS Estimates for Mural Oncology Lowered by HC Wainwright

Mural Oncology plc (NASDAQ:MURA) – HC Wainwright dropped their Q1 2025 earnings per share (EPS) estimates for Mural Oncology in a note issued to investors on Wednesday, March 12th. HC Wainwright analyst A. Maldonado now forecasts that the company will post earnings per share of ($2.13) for the quarter, down from their previous forecast of ($2.05). HC Wainwright has a “Buy” rating and a $18.00 price objective on the stock. The consensus estimate for Mural Oncology’s current full-year earnings is ($7.54) per share. HC Wainwright also issued estimates for Mural Oncology’s Q2 2025 earnings at ($1.26) EPS, Q3 2025 earnings at ($1.17) EPS, Q4 2025 earnings at ($1.10) EPS, FY2025 earnings at ($5.65) EPS, FY2026 earnings at ($3.81) EPS, FY2027 earnings at ($3.41) EPS, FY2028 earnings at ($2.27) EPS and FY2029 earnings at ($1.45) EPS.

Mural Oncology Stock Up 4.4 %

Shares of NASDAQ:MURA opened at $4.07 on Monday. The business has a 50 day moving average price of $3.88 and a 200 day moving average price of $3.60. The company has a market cap of $70.12 million, a price-to-earnings ratio of -0.45 and a beta of 3.66. Mural Oncology has a twelve month low of $2.87 and a twelve month high of $5.12.

Mural Oncology (NASDAQ:MURA) last posted its earnings results on Tuesday, March 11th. The company reported ($2.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.96) by ($0.05). During the same quarter last year, the business posted ($3.57) EPS.

Hedge Funds Weigh In On Mural Oncology

A number of institutional investors and hedge funds have recently bought and sold shares of MURA. Commerce Bank acquired a new stake in Mural Oncology in the 3rd quarter worth $39,000. FMR LLC lifted its stake in shares of Mural Oncology by 124.7% in the third quarter. FMR LLC now owns 20,580 shares of the company’s stock valued at $64,000 after buying an additional 11,423 shares during the period. Jane Street Group LLC acquired a new stake in Mural Oncology during the fourth quarter worth about $68,000. Two Sigma Advisers LP acquired a new stake in Mural Oncology during the fourth quarter worth about $84,000. Finally, Bridgeway Capital Management LLC bought a new position in Mural Oncology during the fourth quarter valued at about $94,000. Institutional investors own 80.21% of the company’s stock.

Mural Oncology Company Profile

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.